Clinical trials: Tardive Dyskinesia
Tardive Dyskinesia
Levetiracetam Treatment of Tardive Dyskinesia
This is a placebo-controlled study designed to learn if levetiracetam is effective for tardive dyskinesia.
- Trial name
- NCT00291213
- Testing
- levetiracetam
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Yale University
Neuroleptic-Induced Tardive Dyskinesia
Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia
We initiate a study with research grant from department of health and Taoyuan mental hospital and choose risperidone and olanzapine as study medications.
- Trial name
- NCT00621998
- Testing
- risperidone, olanzapine
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan
Fibromyalgia, Mitochondrial Diseases
Heart Rate Variability in Response to Metformin Challenge
Diseases caused by brain energy supply defects can be innate (fibromyalgia secondary to familial mitochondrial disorders) or acquired (tardive dyskinesia or weight gain associated with prolonged antipsychotic use).
- Conditions
- Fibromyalgia, Mitochondrial Diseases, Movement Disorders, Diabetes Mellitus, Type 2
- Trial name
- NCT02500628
- Testing
- Metformin
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Woodinville Psychiatric Associates
Schizophrenia, Schizoaffective Disorder
Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia
This study will evaluate the effectiveness of valbenazine on patient- and clinician-reported outcomes assessing health-related quality of life, functioning, and treatment effect in participants with tardive dyskinesia (TD) who…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT05859698
- Testing
- Valbenazine
- Where
- 18 sites in United States
- Volunteers
- 59 people
- Sponsor
- Neurocrine Biosciences
Tardive Dyskinesia
Studying Patterns in Patient Engagement Among Tardive Dyskinesia Patients
The statistical analysis of the collected data aims to reveal the many factors that influence patient involvement in clinical trials.
- Trial name
- NCT06218719
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Schizophrenia, Schizoaffective Disorder
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
To test the feasibility of studying effects of smoking cessation with varenicline on antipsychotic drug-induced neurological side effects, we propose a 12 week pilot study of smoking cessation treatment with varenicline in 10…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Tobacco Smoking, Tardive Dyskinesia
- Trial name
- NCT03495024
- Testing
- Varenicline
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Corporal Michael J. Crescenz VA Medical Center
Schizophrenia and Schizoaffective Disorder, Tardive Dyskinesia
D-Serine Treatment For Tardive Dyskinesia
Presently no generally effective treatments for tardive dyskinesia (TD) are available. D-serine is a naturally occurring amino acid that acts in-vivo as positive allosteric modulator at the glycine site associated with the…
- Trial name
- NCT01804920
- Testing
- D-serine
- Where
- Israel
- Volunteers
- 16 people
- Sponsor
- Herzog Hospital
Extrapyramidal Symptoms, Drug-induced Parkinsonism
A Computer-Assisted Tool for Objective Assessment of Extrapyramidal Symptoms
This prospective, single-center observational study aims to develop and validate a computer-assisted tool for the objective quantitative assessment of extrapyramidal symptoms (EPS).
- Conditions
- Extrapyramidal Symptoms, Drug-induced Parkinsonism, Akathisia, Drug-Induced, Tardive Dyskinesia (TD)
- Trial name
- NCT07715994
- Testing
- Computer-Assisted Objective Assessment of Extrapyramidal Symptoms
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Shanghai Mental Health Center
Tardive Dyskinesia
The Assessment of Movement Disorders Utilizing Live Two-Way Video
The purpose of this project is to determine the equivalency of extrapyramidal symptoms (EPS) and tardive dyskinesia (TD) examinations conducted via live two-way video versus live examinations completed in-person
- Trial name
- NCT01467089
- Testing
- Two way video assessment
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Northwell Health
Tardive Dyskinesia (TD)
Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia
This is a Phase 4, randomized, double-blind, placebo-controlled study to evaluate the persistence of effect of valbenazine 40 mg and 80 mg.
- Trial name
- NCT03891862
- Testing
- Valbenazine
- Where
- 43 sites in United States, Puerto Rico
- Volunteers
- 135 people
- Sponsor
- Neurocrine Biosciences
Tardive Dyskinesia
Piracetam for Treatment Tardive Dyskinesia
The mechanism involved in the development of tardive dyskinesia (TD) is complicated. It now seems that several neurotransmitter systems may be affected, including dopaminergic, noradrenergic, gamma-amino-butyric acid (GABA)…
- Trial name
- NCT00190008
- Testing
- piracetam
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Beersheva Mental Health Center
Schizophrenia, Schizoaffective Disorder
Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia
The objective of the study is to determine whether Panax Ginseng with multiple interactions with key components of brain signaling pathway, can augment the effects of antipsychotics in Schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Tardive Dyskinesia, Insulin Resistance
- Trial name
- NCT00401089
- Testing
- Panax Ginseng
- Where
- 4 sites in Canada, United Kingdom
- Volunteers
- 60 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Tardive Dyskinesia
Efficacy of Docosahexaenoic Acid on Tardive Dyskinesia
Tardive dyskinesia (TD) is a well-known complication of antipsychotic drug therapy in individuals treated for mental disorders such as schizophrenia.
- Trial name
- NCT00621634
- Testing
- Omega-3 fish oil capsules (including DHA)
- Where
- 2 sites in Canada
- Sponsor
- Université de Montréal
Tardive Dyskinesia
Repetitive Transcranial Magnetic Stimulation for the Treatment of the Tardive Dyskinesia.
The purpose of this study is to explore the therapeutic effect and mechanism of transcranial magnetic stimulation (rTMS) in the treatment of the tardive dyskinesia.
- Trial name
- NCT02840760
- Testing
- Repetitive Transcranial Magnetic Stimulation
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Shanghai Mental Health Center
Tardive Dyskinesia, Antipsychotic Agents
Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia
Purpose: Tardive dyskinesia (TD) is a involuntary movement disorder that can occur following long term treatment with antipsychotic medications and for which few treatment options exist.
- Trial name
- NCT03287778
- Testing
- Pyridoxine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia, Tardive Dyskinesia, Metabolic Syndrome
The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial
A short term post-market monitoring of serum prolactin level change among patients with schizophrenia shifting from other antispychotics to different dosages of aripiprazole.
- Trial name
- NCT00468533
- Testing
- Aripiprazole
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- Yu-Li Hospital
Tardive Dyskinesia
Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia
Phase 3, open-label, study to evaluate the safety and tolerability of NBI-98854 administered once daily (qd) for a total of 48 weeks of treatment.
- Trial name
- Kinect 4 (NCT02405091)
- Testing
- NBI-98854
- Where
- 48 sites in United States, Canada and 1 more
- Volunteers
- 167 people
- Sponsor
- Neurocrine Biosciences
Tardive Dyskinesia
Effect of tDCS on Cognition, Symptoms in Chronic Schizophrenia Patients With Tardive Dyskinesia
The aim of the study was to evaluate the efficacy, safety, and cognitive function of transcranial direct current stimulation (tDCS) in chronic schizophrenia patients with tardive dyskinesia (TD).
- Trial name
- NCT03497013
- Testing
- Active tDCS
- Where
- 2 sites in China
- Volunteers
- 64 people
- Sponsor
- Suzhou Psychiatric Hospital
Tardive Dyskinesia
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of two doses (50 and 100 mg) of NBI-98854 administered once daily for the treatment of Tardive Dyskinesia (TD) symptoms.
- Trial name
- NCT01688037
- Testing
- NBI-98854
- Where
- 51 sites in United States, Puerto Rico
- Volunteers
- 109 people
- Sponsor
- Neurocrine Biosciences
Tardive Dyskinesia, Repetitive Transcranial Magnetic Stimulation
Single-Center, Double-Blind, Randomized, Placebo-Controlled Study on Efficacy and Safety of rTMS (With Precise Localization) in Relieving Motor Symptoms of TD
# Brief Summary (English Version) Tardive Dyskinesia (TD) is a hyperkinetic movement disorder induced by long-term use of dopamine receptor blockers and related drugs.
- Trial name
- NCT07173920
- Testing
- repetitive Transcranial Magnetic Stimulation
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Peking University Sixth Hospital